Polycystic Kidney Disease Treatments
Find Polycystic Kidney Disease Treatments
Medications for Polycystic Kidney Disease
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Polycystic Kidney Disease.
Found 4 Approved Drugs for Polycystic Kidney Disease
Tolvaptan
Brand Names
Jynarque, Samsca
Tolvaptan
Brand Names
Jynarque, Samsca
Form: Tablet, Kit
Method of administration: Oral
FDA approval date: May 19, 2009
Classification: Vasopressin V2 Receptor Antagonist
JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). JYNARQUE is a selective vasopressin V 2 -receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) ( 1 )
MetFORMIN
Brand Names
Actoplus, Alogliptin, Dapagliflozin, Glipizide, Glumetza, Glyburide, Glyburide-MetFORMIN, Invokamet, Janumet, Jentadueto, Kazano, Linagliptin, Pioglitazole, Pioglitazone, Riomet, Saxagliptin, Segluromet, Sitagliptin, Synjardy, Trijardy, Xigduo, Zituvimet
MetFORMIN
Brand Names
Actoplus, Alogliptin, Dapagliflozin, Glipizide, Glumetza, Glyburide, Glyburide-MetFORMIN, Invokamet, Janumet, Jentadueto, Kazano, Linagliptin, Pioglitazole, Pioglitazone, Riomet, Saxagliptin, Segluromet, Sitagliptin, Synjardy, Trijardy, Xigduo, Zituvimet
Form: Tablet, Solution
Method of administration: Oral
FDA approval date: January 24, 2002
Classification: Sodium-Glucose Cotransporter 2 Inhibitor
ACTOPLUS MET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use ACTOPLUS MET is not recommended to treat type 1 diabetes mellitus or diabetic ketoacidosis. ACTOPLUS MET is a combination of pioglitazone, a thiazolidinedione agonist of peroxisome proliferator receptor gamma, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1 )
Farxiga
Generic Name
Dapagliflozin
Farxiga
Generic Name
Dapagliflozin
Form: Tablet
Method of administration: Oral
FDA approval date: January 14, 2008
Classification: Sodium-Glucose Cotransporter 2 Inhibitor
FARXIGA (dapagliflozin) is indicated: To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression., To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure., To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors., As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use, FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions.
Empagliflozin
Brand Names
Glyxambi, Jardiance
Empagliflozin
Brand Names
Glyxambi, Jardiance
Form: Tablet
Method of administration: Oral
FDA approval date: August 01, 2014
Classification: Sodium-Glucose Cotransporter 2 Inhibitor
GLYXAMBI is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies (1.
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances